CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring Study

This study investigates the use of CAR-T cell therapy (a type of personalized immune cell treatment) in people with relapsed or treatment-resistant multiple myeloma (a blood cancer) that has spread outside the bone marrow — a condition called extramedullary disease. The study uses advanced imaging and blood tests to monitor how well the treatment works. **You may be eligible if...** - You are over 18 years old - You have a confirmed diagnosis of multiple myeloma - Your myeloma has spread outside the bone marrow (extramedullary disease) visible on imaging - You have already received at least 2 prior treatment lines, including a proteasome inhibitor and an immunomodulatory drug - You are in good health (ECOG 0–1) - Your life expectancy is at least 3 months - Your blood counts meet the minimum requirements for the procedure - You are able to undergo apheresis (a blood cell collection procedure) **You may NOT be eligible if...** - You have not received at least 2 prior lines of therapy - Your myeloma has not spread outside the bone marrow - Your blood counts or organ function are too low - You are unable to undergo apheresis Talk to your doctor to see if this trial is right for you.